Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
April 27 2017 - 8:30AM
Management to host
conference call
WALTHAM, Mass., April 27, 2017 (GLOBE
NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a
clinical-stage biopharmaceutical company focused on the development
of therapies to treat central nervous system (CNS) disorders, today
announced that it will release financial results and business
updates for the first quarter of 2017 on Thursday, May 4,
2017. The Company will host a webcast and conference call
that day at 8:30 a.m. Eastern Time to discuss these results and
updates.
The live call may be accessed by dialing (877)
312-5845 for domestic callers or (765) 507-2618 for international
callers and referring to conference ID number 2971783. A live
webcast of the conference call will be available online in the
Investors and Media section of the Company's website at
ir.minervaneurosciences.com. The archived webcast will be
available on the Company's website beginning approximately two
hours after the event for 30 days.
About
Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva's proprietary compounds include: MIN-101,
in clinical development for schizophrenia; MIN-117, in clinical
development for major depressive disorder (MDD); MIN-202
(JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson's disease.
Minerva's common stock is listed on the NASDAQ Global Market under
the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024